IP Library Granted Patent US 11,813,253
Granted Patent B2
US 11,813,253 · App. 17/554,737 · Granted Nov 14, 2023

Composition and method for proton pump inhibitor suspension

Inventors: Ken Fallin (Diamondhead, MS); Kaity Renaud (Melrose, MA); Peter Mione (Malden, MA); Neal Muni (Wellesley, MA); Anisa Gandhi (Medford, MA)
Assignee: AZURITY PHARMACEUTICALS, INC.
A61K31/4439A61K9/0095A61K47/10A61K47/12A61K47/20A61K47/26A61K47/38A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,813,253
App. No.
17/554,737
Granted
Nov 14, 2023
Kind
B2
Abstract

Suspensions of pump inhibitors (PPIs) are disclosed. The suspension may include a PPI, a copolymer of ethylene oxide and propylene oxide; simethicone emulsion; Sodium Bicarbonate; and Sodium Citrate, USP (Dihydrate). The suspensions have desirable viscosities and enhanced stability.

Claims (133)

1. An oral liquid suspension of a proton pump inhibitor (PPI), comprising:

a PPI;

0.4%-0.6% (w/v) benzyl alcohol;

1.0%-6.0% (w/v) a copolymer of ethylene oxide and propylene oxide;

0.1%-0.3% (w/v) simethicone emulsion (30%);

8.0%-8.8% (w/v) sodium bicarbonate;

0.5%-1.5% (w/v) sodium citrate (dihydrate);

a sweetener that comprises ammonium glycyrrhizate and sucralose;

a thickening agent that is xanthan gum, hydroxyethylcellulose, or a combination thereof; and

water; and

wherein the formulation retains homogeneity of less than +/−5% of variation for the PPI by assay after at least 30 days stored at 5° C.

2. The suspension of claim 1 , wherein the PPI is lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole.

3. The suspension of claim 1 , wherein the PPI is lansoprazole and is present at 3 mg/mL in the suspension.

4. The suspension of claim 1 , wherein the PPI is esomeprazole.

5. The suspension of claim 1 , wherein the PPI is rabeprazole.

6. The suspension of claim 1 , wherein the PPI is pantoprazole.

7. The suspension of claim 1 , wherein the PPI is dexlansoprazole.

8. The suspension of claim 1 , wherein the pH of the suspension is at least pH 8.0.

9. The suspension of claim 1 , wherein the copolymer of ethylene oxide and propylene oxide is Poloxamer 188.

10. The suspension of claim 1 , wherein the sweetener further comprises sorbitol.

11. The suspension of claim 1 , further comprising propylene glycol.

12. The suspension of claim 1 , wherein the dynamic viscosity is greater than or equal to 50 and less than or equal to 1000 centipoise (cP) when determined at 6 rpm and 25° C.

13. The suspension of claim 1 , wherein the suspension is stable for at least 30 days when stored at 2-8 degrees Celsius.

14. The suspension of claim 1 , wherein the suspension includes the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.5% (w/v) benzyl alcohol;

0.003% (w/v) FD&C Red No. 40;

0.15% (w/v) strawberry flavor;

0.35% (w/v) hydroxyethylcellulose;

2.00-4.00% (w/v) Poloxamer 188;

5.0% (w/v) propylene glycol;

0.2% (w/v) simethicone emulsion (30%);

8.4% (w/v) sodium bicarbonate;

1.0% (w/v) sodium citrate (dihydrate);

ammonium glycyrrhizate and 0.45% (w/v) sucralose;

0.4% (w/v) xanthan gum; and

purified water.

15. The suspension of claim 1 , wherein the suspension includes the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.5% (w/v) benzyl alcohol;

0.003% (w/v) FD&C Red No. 40;

0.15% (w/v) strawberry flavor;

0.07% (w/v) ammonium glycyrrhizate;

0.25% (w/v) hydroxyethylcellulose;

2.0% (w/v) Poloxamer 188;

0.08% (w/v) saccharin sodium;

0.2% (w/v) simethicone emulsion (30%);

8.4% (w/v) sodium bicarbonate;

1.0% (w/v) sodium citrate (dihydrate);

2.5% (w/v) sorbitol solution (70%);

0.4% (w/v) sucralose; and

purified water.

16. The suspension of claim 1 , wherein the suspension comprises the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.4%-0.6% (w/v) benzyl alcohol;

0.2%-0.5% (w/v) hydroxyethylcellulose;

1.0%-6.0% (w/v) Poloxamer 188;

0.1%-0.3% (w/v) simethicone emulsion (30%);

8.0%-8.8% (w/v) sodium bicarbonate;

0.5%-1.5% (w/v) sodium citrate (dihydrate);

ammonium glycyrrhizate and 0.35%-0.5% (w/v) sucralose;

1.5%-4% (w/v) sorbitol solution; and

8%-12% (w/v) glycerin 99.7%.

17. The suspension of claim 1 , wherein the suspension consists essentially of the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.4%-0.6% (w/v) benzyl alcohol;

0.002%-0.005% (w/v) FD&C Red No. 40;

0.1%-0.2% (w/v) strawberry flavor;

0.2%-0.5% (w/v) hydroxyethylcellulose;

1.0%-6.0% (w/v) Poloxamer 188;

0.1%-0.3% (w/v) simethicone emulsion (30%);

8.0%-8.8% (w/v) sodium bicarbonate;

0.5%-1.5% (w/v) sodium citrate (dihydrate);

ammonium glycyrrhizate and 0.35%-0.5% (w/v) sucralose;

purified water;

1.5%-4% (w/v) sorbitol solution; and

8%-12% (w/v) glycerin 99.7%.

18. The suspension of claim 1 , wherein the suspension consists essentially of the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.5% (w/v) benzyl alcohol;

0.003% (w/v) FD&C Red No. 40;

0.15% (w/v) strawberry flavor;

0.35% (w/v) hydroxyethylcellulose;

2.0% (w/v) Poloxamer 188;

0.15% (w/v) simethicone emulsion (30%);

8.4% (w/v) sodium bicarbonate;

1.0% (w/v) sodium citrate (dihydrate);

ammonium glycyrrhizate and 0.4% (w/v) sucralose;

purified water;

2.5% (w/v) sorbitol solution; and

10% (w/v) glycerin 99.7%.

19. The suspension of claim 1 , wherein the suspension consists essentially of the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.5% (w/v) benzyl alcohol;

0.003% (w/v) FD&C Red No. 40;

0.15% (w/v) strawberry flavor;

0.35% (w/v) hydroxyethylcellulose;

4.0% (w/v) Poloxamer 188;

0.15% (w/v) simethicone emulsion (30%);

8.4% (w/v) sodium bicarbonate;

1.0% (w/v) sodium citrate (dihydrate);

ammonium glycyrrhizate and 0.4% (w/v) sucralose;

purified water;

2.5% (w/v) sorbitol solution; and

10% (w/v) glycerin 99.7%.

20. The suspension of claim 1 , wherein the suspension consists essentially of the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.4-0.6% (w/v) benzyl alcohol;

0.002-0.005% (w/v) dye;

0.1-0.2% (w/v) flavoring;

0.06-0.08% (w/v) ammonium glycyrrhizate;

1.00-3.00% (w/v) Poloxamer 188;

4.0-6.0% (w/v) propylene glycol;

0.1-0.3% (w/v) simethicone emulsion;

8.0-8.8% (w/v) sodium bicarbonate;

0.5-1.5% (w/v) sodium citrate (dihydrate);

0.4-0.45% (w/v) sucralose;

0.3-0.5% (w/v) xanthan gum; and

purified water.

21. The suspension of claim 1 , wherein the suspension consists essentially of the following:

lansoprazole, esomeprazole, rabeprazole, pantoprazole, or dexlansoprazole;

0.5% (w/v) benzyl alcohol;

0.003% (w/v) FD&C Red No. 40;

0.15% (w/v) strawberry flavor;

0.07% (w/v) ammonium glycyrrhizate;

2.00% (w/v) Poloxamer 188;

5.0% (w/v) propylene glycol;

0.2% (w/v) simethicone emulsion (30%);

8.4% (w/v) sodium bicarbonate;

1.0% (w/v) sodium citrate (dihydrate);

0.45% (w/v) sucralose;

0.4% (w/v) xanthan gum; and

purified water.

Assignments (3)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: FALLIN, KEN; RENAUD, KAITY; MIONE, PETER; MUNI, NEAL; GANDHI, ANISA
To: CUTISPHARMA, INC.
Reel/Frame 058655/0187 →
CHANGE OF NAME Recorded Jan 14, 2022
From: CUTISPHARMA, INC.
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 058740/0535 →
Continuity (3)
Continuation 16310675
Provisional Application 62351271 · Jun 16, 2016
Related Publication 20220152007A1 · May 19, 2022